



Ipilimumab

REJECTED

The Expert Committee, after evaluation, declines to list the medicine proposed in the application.
The Model List of Essential Medicines reports reasons that Committee Members have identified for denying listing.

General description

| | |
|--------------------|---|
| INN | Ipilimumab |
| ATC codes | L01FX04 |
| Medicine type | Biological agent |
| EML status history | Application rejected in 2025 (TRS 1064) for Melanoma of skin Application rejected in 2025 (TRS 1064) for Renal cell carcinoma of kidney, except renal pelvis Application rejected in 2025 (TRS 1064) for Squamous cell carcinoma of oesophagus Application rejected in 2025 (TRS 1064) for Other specified malignant neoplasms of bronchus or lung |
| Wikipedia | Ipilimumab  |
| DrugBank | Ipilimumab  |

Recommendations

Section Immunomodulators

Parenteral > General injections > IV: 5 mg per mL in 10 mL vial concentrate for solution for infusion; 20 mg per mL in 40 mL vial concentrate for solution for infusion

Indications

Melanoma of skin

Renal cell carcinoma of kidney, except renal pelvis

Squamous cell carcinoma of oesophagus

Other specified malignant neoplasms of bronchus or lung

